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1. Introduction 
Myopathy, which clinically shows muscular pain (myalgia), weakness, cramps, stiffness 
and spasm, is one of neuromuscular disorders due to inflammation and/or dysfunction of 
muscle fibers. “Myositis”, which is a general term for inflammation of the muscle, is 
pathologically an inflammatory myopathy seen seen mainly in autoimmune disorders 
including dermatomyositis (DM). The myopathy is classified by National Institute of 
Neurological Disorders and Stroke (NINDS) as indicated in Table 1 (1). We here focus 
myopathy on primary Sjögren’s syndrome (pSjS) associated with myalgia “mimicking 
DM”, as previously reported (2), and the inflammatory myopathy of DM (Table 2). Most 
of SjS is a secondary disorder to systemic autoimmune diseases including systemic lupus 
erythematosus (SLE), systemic sclerosis, DM, and so on. However, SjS, which is not 
associated with other autoimmune diseases, is considered to be an idiopathic primary 
disorder characterized by sicca symptoms. It is known that pSjS may be associated  
with fever, fatigue, myalgia, arthralgia, cutaneous vasculitis, etc. in addition to sicca 
symptoms (4-8). 
DM is also characterized by myalgia, muscular weakness and fatigue due to inflammatory 
myopathy that ultimately progresses to muscle degeneration and the cutaneous 
involvements. The skin manifestations include helio-trope-like colored erythema and 
swelling on the eye-lids, cheeks, neck and upper extremities of the sun-exposed areas and 
Gottron’s papules on the dorsa of the hand fingers (3). Although the etiology of DM remains 
unknown, internal maligmant disorders including lung and/or other organ cancers are 
frequently associated. Generally DM is classified as shown in Table 3 (9).  
                                                 
* Corresponding Author 
 
Neuromuscular Disorders 
 
118 
Congenital myopathies: characterized by developmental delays in motor skills; skeletal 
and facial abnormalities are occationally evident at birth 
Muscular dystrophies: caused by progressive weakness in voluntary muscles; sometimes 
evident at birth 
Mitochondrial myopathies: caused by genetic abnormalities in mitochondria, cellular 
structures that control energy; include Kearns-Sayre syndrome, 
Glycogen storage diseases of muscle: caused by mutations in genes controlling enzymes 
that metabolize glycogen and glucose (blood sugar); include Pompe’s, Anderson’s and 
Cori’s disease 
Myoglobulinurias: caused by disorders in the metabolisum of a fuel (myoglobulin) 
necessary for muscle work; include McArdle, Tarui and DiMauro diseases 
Dermatomyositis: an inflammatory myopathy and skin lesions 
Myositis ossificans: characterized by bone growing in muscle tissue 
Familiar periodic paralysis: characterized by episodes of weakness in arms and legs 
Polymyositis inclusion body myositis and related myopathies: inflammatory 
myopathies of skeletal muscles 
Neuromyotonia: characterized by alternating episodes of twiching and stiffness 
Stiff-man syndrome: characterized by episodes of rigidity and reflex spasms 
Common muscular cramps and stiffness and tetany: characterized by prologed spasms 
of the arms and legs
(National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA1) 
Table 1. Classification of myopathy  
 
Patient Gender 
Age 
years 
Disease Enzyme 
Muscle 
biopsy 
Auto-
antibody
Observation 
term 
Compli-
cation 
Outcome 
1. F 37 pSjS 
No 
abnormatities
myopathy 
ANA nv
SSA 61.4
SSB 21.6 
3.0 y no remission 
2. M 32 pSjS 
CK 147 
ALD 5.8 
myopathy 
ANA 20 
SSB 15.7 
8 m no remission 
3. F 29 DM 
CK 883 
ALD 11.2 
myositis nv 2.6 y no remission 
4. F 42 DM 
CK 212 
KL-6 2485 
nd nv 4.3 y 
intestinal 
peumonia 
remission 
5. M 45 DM 
CK 302 
ALD 8.4 
myositis nv 3.8 y no remission 
6. F 55 DM SLD 5.7 nd nv 3.11 y no remission 
7. F 60 DM CK 364 nd nv 2.0 y no remission 
8. M 66 DM 
CK 1706 
ALD 8.2 
KL-6 1876 
myoglobin 
29.7 
myositis ANA 20 2.0 y 
pneumonia 
and cancer 
death 
ALD: aldolase, ANA: anti-nuclear antibody, CK: creatine kinase, DM: dermatomyositis, 
F: female, M: male, nd: not done, Nv: negative, pSjS: primary Sjögren’s syndrome,  
SSA: anti-SjS A antibody, SSB: anti-SjS B antibody 
Myopathy: non-inflammatory myopathy, Myositis: inflammatory myopathy  
Table 2. Myopathy and myositis in primary Sjögren’s syndrome (pSjS) and dermatomyositis 
(DM) 
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 Dermatomyosistis 
 Without muscle weakness (amyopathic dermatomyositis or dermatomyositis  
sine myositis) 
 With muscle weakness 
 Adult 
 associated with cancer 
 not associated with cancer 
 Pediatric 
 Polymyositis 
 Adult 
 Pediatric 
 Inclusion-body myositis 
 Overlap (myositis associated with a connective tissue disease) 
Drake LA, et al9.: Guidelines of care of dermatomyositis. J Am Acard Dermatol 1996; 34: 824  
Table 3. Classification of Dermatomyositis/ Polymyositis 
2. Cases  
pSjS: A 37-year-old woman (Case 1 in Table 2) was suffered from fever around 37.5℃, 
fatigue, proximal muscle pain and weakness in her limbs and arthralgia since a week before 
her visiting our hospital. She presented herself with swelling and helio-trope-like colored 
erythema on the eye-lids (Fig. 1a,b), purpurish erythema-spots on the elbows, thin-reddish 
erythema patches on the legs (Fig.1c) and red palms. On the dorsa of the hand-fingers, the 
eruption looked like Gottron’s papules was seen and thin purpuric spots were also noted on 
the paronychial areas. The electromyography showed low amplitude motor units (less than 
1 mV) from muscles of the upper extremities that were suggestive myopathy. We suspected 
the patient had DM and the skin biopsy was taken from the erythematous patches on the 
left leg. The histology revealed so-called “lymphocytic vasculitis” which showed swollen 
 
a) 
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b) 
 
c) 
Fig. 1. a,b) Close-up view of the right upper eye-lid showing slightly swollen and helio-
trope-like colored erythema (Case 1 in Table 2). c) Gottron’s nodule-like eruption on the 
dorsa of the fingers and thin-reddish erythematous patches on the lower legs. 
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vascular walls surrounded by mainly monocytes and a few of neutrophils in the middle and 
deep dermis (Fig. 2a,b). No deposit of IgG, IgA, IgM and C3 was seen at the dermo-
epidermal (D-E) junction and vascular walls in the dermis by immunofluorescent 
microscopy. The immunochemical histology revealed CD4+>CD8+>CD56+ cells distributed 
around vessels in the deep dermis. A muscle biopsy was performed from the biceps muscle 
of the left-upper arm where the patient was complaining of pain. No features of 
inflammation associated the “muscle fiber degeneration” could be found though slight 
vascular infiltration was seen in the interstitial tissue.  
  
a)      b) 
Fig. 2. a) A skin biopsy from the left side of the lower leg revealed, a. vascular infiltration with 
lymphoid cells and a few neutrophils in the middle and deep dermis (H&E stain, x40). b) The 
magnified view showed swelling of the vascular endothelial cells with slight degeneration 
infiltrated by lymphoid cells, suggesting so-called “lymphocytic vasculitis” (x 200) 
Laboratory examinations revealed within normal-limit (WNL) ranges of white blood cells 
(WBC), red blood cells (RBC) and serum AST (aspartate aminotransferase), ALT (alanine 
aminotransferase), and CK (creatine kinase) (28 IU/L, WNL: 48~259) and aldolase (ALD) 
(2.2 IU/L,  WNL: 2.5~5.6) were rather lower than WNL. The serum levels of complement 
were high in CH50 (58.4 u/ml, WNL: 31.0~48.0) but levels of C3 and C4 were WNL. 
Although auto-antibodies (auto-Abs) including anti-nuclear Ab (ANA), anti-Jo-1, anti-DNA 
and anti-acetylcholine receptor Abs and RA factor were negative, anti-Sjögren’s syndrome A 
(anti-SSA) and anti-SSB Abs showed the titers of 61.4 and 21.6 (WNL: less than 1.0 ), 
respectively, which were highly positive in detection by ELISA. Serum carcinoembryonic 
antigen (CEA) was not detected. Urinalysis revealed no abnormalities except detection of 
acetone body. The chest X-ray and positron emission tomography (PET) with 18FDG (2-
deoxy-2-fluoro-D-glucose) were performed but no abnormal uptakes were detected except 
for an enlarged lymphnode at the right-side neck and slight enlargement of the liver and 
spleen. Ophthalmological examinations revealed positive Schirmer’s test (10mm/6mm) and 
fluorescein test which showed dry-eyes, although the amount of saliva was 3.5 ml/10 min 
which seemed to be low But WNL. The pain of visual analog scale (VAS) score was 75 mm 
when she initially visited our clinic.  
The patient was diagnosed as having pSjS with myalgia mimicking DM, which may be 
classified as the extraglandular type. She was treated with prednisolone (PSL) 20mg/day 
and non-steroidal anti-inflammatory drugs (NSAIDs). The symptoms including the 
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cutaneous manifestations completely disappeared and pain VAS score also gradually 
decreased to 55 mm in a week. The patient was quickly recovered from fatigue, subfebrile 
state, myalgia and arthralgia two weeks after treatment by oral steroid. However, PSL 
administration of within 10 mg/day was needed to keep her well condition, although more 
than two years have been passed since her first visit.  
Although the other 32 year-old male patient (Case 2) complained of dry eyes, mild fever, 
myalgia and muscle weakness of the upper extremities for more than one year, we initially 
suspected DM and examined for possibility of his having SjS regardless of absence of a DM-
like eruption. Ophthalmologically he was suggested to have SjS. The blood examination 
revealed ALT 40 U/L (WNL: 6-36), ALD 5.8 IU/L, titers of ANA 20x (speckled type) and 
anti-SSA Ab 15.7 which were relatively high. However, a biopsy from the biceps muscle of 
the left upper arm was free from inflammation, and no internal malignancy was associated 
through examinations including PET with 18FDG. He has been followed as pSjS similarly to 
the Case 1 for the duration of more than half a year.  
DM: A 29 year-old female (Case 3) visited our clinic for helio-trope-like eruptions on the 
sun-exposed areas including upper eye-lids, cheeks and V-neck area (Fig. 3a), swollen 
fingers with periungual hemorrhage of the hands (Fig. 3b) and myalgia of the upper 
extremities. The examination revealed a rise of AST and ALT (65 and 46 U/L; WNL: 35-11 
and 39-6, respectively), CK 883 U/L and ADL 11.2 IU/L, but no auto-Abs including ANA, 
anti- SSA and SSB Abs were found. No internal malignancies were found. However, a 
biopsy from left biceps muscle revealed the typical myositis with intersititial vascular 
infiltration (Fig. 4a). The immunochemistry of infiltrated cells around the interstitial vessels 
of the muscle tissue revealed CD4+> CD8+> CD68+ cells and little of CD20+ cells as similarly 
seen in the cutaneous findings of Case 1 (Fig.4b). We made a diagnosis of early stage of DM. 
    
a)      b)  
Fig. 3. a) A 29 year-old female with dermatomyositis (DM) (Case 3). Swollen helio-trope-like 
erthema on the upper eye-lids and cheeks. b) Swollen erythema on the dorsa of the hands 
and periungual hamorrhage of the fingers. 
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a)     b) 
 
Fig. 4. a) A biopsy specimen of muscle tissue from the left biceps muscle of patient with 
dermatomyositis (DM) (Case 3). Lymphoid cell infiltration around the vessels was found in 
the interstitial tissue (HE, 200x). b) Immunohistology of CD4+T cells in the interstitial 
perivascular infiltration of the biceps muscle (Avidin-biotin stain, 20x). The infiltrated cells 
are CD4+>CD8+>CD56+ mononuclear cells. 
A 66 years old man (Case 8) was referred to our clinic for sudden episode of helio-trope-
like colored erythematous eruption on the sun-exposed areas including the face, V-neck 
area, upper back and upper extremities associated with “myopathy” exhibiting muscle 
weakness and myalgia (Fig. 5). The patient had heavily smoked cigarettes a pack or more 
a day. He was initially suspected to have photosensitive dermatitis due to some 
photosensitizer and/ or DM and the examinations including skin and muscle biopsy from 
left-upper arm were performed. Laboratory examinations revealed WBC 11,070 /μl, RBC 
327 x 104 /μl , CRP 14.28 mg/dL (WNL: 0.30), WNL of serum transaminases (AST and 
ALT), high levels of CK 1,706 U/L (WNL: 259-2.5) , ALD 8.2 IU/L (WNL: 5.6-2.5), 
myoglobulin-U 29.7 ng/mg (WNL: 10~0) and KL-6 1876 U/mL (WNL: 499-0). The titers of 
auto-Abs showed WNL as to anti-DNA, anti-Jo-1, anti-RNP, Sm, and anti-SSA and anti-
SSB Abs except for ANA 20x (speckled type). Although CEA, CA15-3, AFP-L3, -L2,-L2, 3 
and CA602 were negative, we suspected the patient might have an association with lung 
carcinoma after the chest X-ray and CT examination. The skin histology of the helio-trope- 
like erythema revealed as SLE-like findings exhibiting liquefaction degeneration of the D-
E junction and edema of the upper dermis with a little lymphoid cell infiltration (Fig. 6) 
and immunohistologically, IgG, IgM and complement C3 were linearly deposited at the 
D-E junction. The muscle biopsy from the biceps of the left arm exhibiting myalgia shows 
a tiny interstitial perivascular infiltration between the muscle bundles, suggesting 
“myositis”, although obvious muscular-degeneration was not found. The symptoms of 
the skin rash and myalgia of the extemities were improved temporary after treatment 
with oral PSL and NSAIDs. However, the patient died by lung cancer 2 years after his first 
visit to our clinic.  
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Fig. 5. A 66 years old patient with DM (Case 8) associated with lung cancer. Helio-trope-like 
erythema can be seen on the face and upper breast (so-called sun exposed areas). 
 
Fig. 6. A biopsy specimen of the helio-trope-like erythema from the upper chest.  
Liquefaction degeneration can be seen at the D-E junction and edema and a few lymphoid 
cell infiltration are present in the upper dermis (HE, 200x). 
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3. Discussion 
It is rare to see the cases of pSjS with myalgia in Japan, but about 30 % of pSjS patients are 
reported to be associated with muscle involvement known as fibromyalgia in US and 
European countries (5, 6). The main cutaneous involvement is purpura, annular shaped 
erythema and/or macules, erythematous papules and ischemic ulcers due to microvasculitis 
in pSjS (7, 8). In this patient (Case 1 in Table 2), the cutaneous eruptions including the 
swollen and helio-trope-like colored erythema on the eye-lids, thin-reddish macules on the 
limbs, purpuric spots and Gottron’s papule-like eruption on the dorsa of the fingers were 
recognized and quickly disappeared after administration with low dose of PSL. Although 
the clinical signs-like DM did not reappear by the treatment, the continuous treatment with 
PSL seems to be still needed. As reported that this disorder is a bothersome and slowly 
progressive disease (10-12), we should follow the clinical course whether the patient might 
develop lymphoproliferative disorders in a near future because the enlargement of the 
lymphnode and hepatosplenomegaly was noted initially. Regarding Case 2, the clinical 
symptoms and laboratory examination were suggestive of DM associated with SjS without 
the skin manifestations. We considered him as having pSjS associated with myopathy 
because dry-eye symptoms, positive anti-SSA Ab and no cutaneous symptom of DM were 
noted. Although these 2 cases of pSjS were associated with myalgia, the cause of their 
myopathy is not clear because no inflammation was found in the biopy specimens from 
their biceps muscle. However, it is reported that the myopathy might be due to small-vessel 
injury by auto-Abs or circulating immune complexes because electrondence deposits were 
noted (13). As to the infiltrated cells around the vessels in the cutaneous lesion, the CD4+ T 
cells were dominant as similar to the findings in myositis of patients with DM.  
DM is an idiopathic inflammatory disorder characterized by inflammatory myopathy, 
indicating myositis, and skin manifestations and it can be associated with the secondary SjS 
sometimes. The etiology is still unknown and the prevalence is estimated as 1-10 cases per 
million population, but in children 3.2 cases per million which are distributed in the whole 
world (3). The clinical types of DM are classified in Table 3 and the internal malignancies are 
frequently associated in the adult type of DM. The risk is reported to be a 6.5-fold higher 
than ordinary persons after 45 years of age (14). Regarding myopathy in DM patients it 
might be characterized by inflammatory myopathy progressing to myositis and 
degeneration of muscle fibers, and the helio-trope-like eruptions on the sun-exposed areas 
showed SLE-like changes histologically. On the other hand, there are the cases associated 
without myogenic symptoms in DM, which is called as “amyopathic DM” (DM sine 
myositis). However, these cases should be considered as “pre-myopathic DM” because they 
might Be rather early diagnosed (15). Though the direct cause of myopathy is still unknown, 
there are some pathogeneses reported, such as the presences of myositis- specific auto-Abs 
(15,16) and inflammatory cytokines from T cells including interleukin (IL)-17 and IL-23 in 
early stage of patients with DM (18). The study regarding Th1/Th2 balance showed that Th2 
cell predominance was suggested in patients with active stage of DM (19). In plasma of 
patients with DM and/or polymyositis, microparticles derived from CD14+ mononuclear 
cells, CD3+ T cells and CD19+ B cells were found to be elevated by electron microscopic 
examination, which suggests these diseases were immunological disorders (20). It is 
reported that CD19+CD23+ cells are increased and that CD4+CD45RO+ cells are decreased in 
the peripheral blood of patients with DM, suggesting reduction of regulatory T cells (21).  It 
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was also suggested that CD4+CD25+ cells, forkhead/winged helix transcription factor (Fox 
P3)+, transforming growth factor+ and IL-10+ cells were reduced in peripheral blood of 
patients with DM (21). Actually, CD4+CD8+ cells were significantly distributed around 
vessels in the interstitial tissues of the muscle bundles in our patients with DM. These cells 
might be CD4+CD 28+ (null) cells and CD8+CD28+ (null) cell infiltration, as reported, and it 
is of interest that circulating CD4+CD28+ cells and CD8+CD28+ cells were significantly 
increased in seropositive individuals, responded to human cytomegalovirus antigen 
stimulation and correlated with disease duration (22).  
As to treatment for myopathy of patients with pSjS and DM, adequate doses of NSAIDs 
and/or oral steroids were mainly used in corresponding to their clinical severities and these 
were considered to be effective. However, in addition to these drugs, the combination with 
immunosuppressive agents such as azathioprine, cyclosporine, mycophenolate or 
methotrexate should be used for the autoimmune diseases, if they were not clinically 
controlled. The biological agent, rituximab, and tacrolimus may offer additional benefit to 
some patients and emerging agents against T cells, B cells, transmigration or transduction 
molecules may be discussed as New treatments (23).  
4. Conclusion 
Myopathies are neuromuscular disorders exhibiting myalgia and muscular weakness due to 
dysfunction of muscle fibers which are frequently seen in autoimmune diseases. We here 
discussed about the non-inflammatory myopathy seen in patients with pSjS and the 
inflammatory myopathy, that is myositis, found in patients with DM is suggested to be 
Immunological dysfunction in pathogenesis. Although the mechanism of the myopathy is still 
unclear, it might be due to inflammatory cytokines released from CD4+CD 28+ (null) cells and 
CD8+CD28+ (null) cells infiltrated around vessels in the muscles of patients with MD.  
5. Abbreviations  
Ab, antibody; ALD, aldolase; ANA, anti-nuclear antibody; anti-SSA Ab, anti- Sjögren’s 
syndrome A Ab; anti-SSB Ab, anti- Sjögren’s syndrome B Ab; CK, creatine kinase; D-E 
junction, dermo-epidermal junction; DM, dermatomyositis; IL, interleukin; NSAID, non-
steroidal anti-inflammatory drug; pSjS, primary Sjögren’s syndrome; PSL, prednisolone; 
VAS, visual analog scale; WNL, within normal limit 
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